🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesMy blood pressure normalization journey — what worked for you? Page 2

My blood pressure normalization journey — what worked for you?

tane_welly Thu, Dec 5, 2024 at 7:34 PM 13 replies 1,917 viewsPage 2 of 3
Dr.MetabolicMD
VIP Member
2,345
16,789
Jan 2024
Rochester, MN
Dec 7, 2024 at 7:59 AM#6
Dr.ReproEndo said:
tane_welly said: ...we don't know the long-term effects of cardiovascular risk...

This is where I part company with the consensus forming above. The "earlier than weight loss explains" argument is weaker than this thread makes it sound. Blood pressure and inflammatory markers move fast and are downstream of early weight loss, so the mechanism is not as cleanly separable as the summaries imply.

28 6SleepDoc_PDX, RegAffairsDC, BiostatsBrad and 25 others
Reply Quote Save Share Report
kate.chem
VIP Member
3,890
17,654
Dec 2023
California
Dec 7, 2024 at 10:33 PM#7
tane_welly said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).

From SELECT trial: MACE at 39 months — 6.5% semaglutide vs 8.0% placebo. ARR = 1.5%. NNT = 67 over 3.3 years.

Compare to established therapies:

InterventionNNTTimeframe
Semaglutide (MACE)673.3 years
Statins primary prevention (MI)~1005 years
Aspirin secondary prevention~772 years

These NNTs are clinically meaningful and comparable to accepted cardiovascular interventions.

Last edited: Dec 8, 2024 at 1:33 AM
29 7VanRx_Mike, steve_okc, dave_SLC and 26 others
Reply Quote Save Share Report
Dr.GastroMayo
VIP Member
2,345
13,456
Jan 2024
Mayo Clinic, MN
Dec 8, 2024 at 1:07 PM#8
Dr.MetabolicMD said:
The "earlier than weight loss explains" argument is weaker than this thread makes it sound.

6 month update on cardiovascular risk: down 41 lbs, off blood pressure meds, A1C normalized. Genuinely life-changing.

30 8COA_Karl, MikeFit_NJ, InsuranceTom and 27 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
B12Beth
Member
289
890
Oct 2024
Maryland
Dec 9, 2024 at 3:42 AM#9

A narrower follow-up, since the general answer is now clear:

Did your prescriber agree with that reading, and if not what was their objection?

31 9marco_milano, pam_columbus, nick_SD_fit and 28 others
Reply Quote Save Share Report
tane_welly
Member
234
1,123
Sep 2024
Wellington, NZ
Dec 12, 2024 at 1:41 AM#10
Dr.GastroMayo said:
6 month update on cardiovascular risk: down 41 lbs, off blood pressure meds, A1C normalized.

Lp(a) and cardiovascular risk: a nuance that matters. Unlike most lipid markers, Lp(a) is 90%+ genetically determined and doesn't really change with weight loss or GLP-1 therapy.

My Lp(a) has remained at 60 nmol/L across all time points. If yours is elevated (>50 nmol/L), you need additional risk mitigation strategies regardless of your GLP-1 response. Don't assume your medication is covering all cardiovascular risk factors.

Last edited: Dec 12, 2024 at 4:41 AM
1 24pam_columbus
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register